Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR4 | Q13639 | 9/20 | 0.49 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.45 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.44 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.44 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
| ▸ | HTR1D | P28221 | 1/20 | 0.44 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.44 |
| ▸ | HTR2B | P41595 | 1/20 | 0.44 |
| ▸ | HTR3A | P46098 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13667126 | 0.86 | HTR4 (0.53) | HTR4MCHR1CHRM4CHRM5ADRA2C | |
| SCHEMBL13635104 | 0.83 | HTR4 (0.56) | HTR4MCHR1CHRM4CHRM5ADRA2C | |
| SCHEMBL12377356 | 0.83 | HTR4 (0.53) | HTR4MCHR1CHRM4CHRM5ADRA2C | |
| SCHEMBL13634964 | 0.82 | HTR4 (0.49) | HTR4MCHR1CHRM4CHRM5ADRA2C | |
| SCHEMBL13634894 | 0.81 | HTR4 (0.51) | HTR4MCHR1CHRM4CHRM5ADRA2C | |
| SCHEMBL3546076 | 0.81 | HDAC4 (0.52) | ALDH1A1 | |
| SCHEMBL1560209 | 0.81 | HTR4 (0.64) | HTR4MCHR1CHRM4CHRM5ADRA2C | |
| SCHEMBL12825887 | 0.81 | HTR4 (0.66) | HTR4MCHR1CHRM4CHRM5ADRA2C | |
| SCHEMBL12426368 | 0.81 | HPGDS (0.47) | HTR4 | |
| SCHEMBL1560585 | 0.80 | HTR4 (0.58) | HTR4MCHR1CHRM4CHRM5ADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110190306-A1 | Inhibitors of PLK | CHROMA THERAPEUTICS LTD. (GB) | 2011-08-04 | — | — | US | disclosed |
| WO-2009130453-A1 | INHIBITORS OF PLK | CHROMA THERAPEUTICS LTD. (GB) | 2009-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190306-A1 | Inhibitors of PLK | PLK3, PLK2, PLK4 | HTR4 1456/4885MCHR1 4122/4885KCNA3 1665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.